Suppr超能文献

肝硬化中的营养不良:肌肉减少症对代谢和临床反应的影响和后果。

Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses.

机构信息

Department of Gastroenterology, Metrohealth Medical Center, 2500 Metrohealth Drive, Cleveland, OH 44109, USA.

出版信息

Clin Liver Dis. 2012 Feb;16(1):95-131. doi: 10.1016/j.cld.2011.12.009. Epub 2012 Jan 23.

Abstract

Malnutrition is the most common, reversible complication of cirrhosis that adversely affects survival, response to other complications, and quality of life. Sarcopenia, or loss of skeletal muscle mass, and loss of adipose tissue and altered substrate use as a source of energy are the 2 major components of malnutrition in cirrhosis. Current therapies include high protein supplementation especially as a late evening snack. Exercise protocols have the potential of aggravating hyperammonemia and portal hypertension. Recent advances in understanding the molecular regulation of muscle mass has helped identify potential novel therapeutic targets including myostatin antagonists, and mTOR resistance.

摘要

营养不良是肝硬化最常见的、可逆转的并发症,它会对生存、对其他并发症的反应和生活质量产生不利影响。肌肉减少症(骨骼肌质量的丧失)和脂肪组织丧失以及改变底物的利用作为能量来源是肝硬化中营养不良的 2 个主要成分。目前的治疗方法包括高蛋白补充,特别是作为深夜小吃。运动方案有可能加重血氨过多和门静脉高压。最近在理解肌肉质量的分子调节方面的进展有助于确定潜在的新的治疗靶点,包括肌肉生长抑制素拮抗剂和 mTOR 抵抗。

相似文献

1
Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses.
Clin Liver Dis. 2012 Feb;16(1):95-131. doi: 10.1016/j.cld.2011.12.009. Epub 2012 Jan 23.
2
Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis.
Int J Mol Sci. 2020 Jul 28;21(15):5357. doi: 10.3390/ijms21155357.
3
Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.
Alcohol Clin Exp Res. 2017 Aug;41(8):1419-1431. doi: 10.1111/acer.13425. Epub 2017 Jul 11.
4
Sarcopenia in cirrhosis: from pathogenesis to interventions.
J Gastroenterol. 2019 Oct;54(10):845-859. doi: 10.1007/s00535-019-01605-6. Epub 2019 Aug 7.
5
Cause and management of muscle wasting in chronic liver disease.
Curr Opin Gastroenterol. 2016 May;32(3):159-65. doi: 10.1097/MOG.0000000000000261.
6
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis.
J Gastroenterol Hepatol. 2012 Mar;27(3):430-41. doi: 10.1111/j.1440-1746.2011.06951.x.
8
Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.
Aliment Pharmacol Ther. 2020 Jan;51(1):64-77. doi: 10.1111/apt.15571. Epub 2019 Nov 8.
9
Treatment to improve nutrition and functional capacity evaluation in liver transplant candidates.
Curr Treat Options Gastroenterol. 2014 Jun;12(2):242-55. doi: 10.1007/s11938-014-0016-9.
10
Sarcopenia from mechanism to diagnosis and treatment in liver disease.
J Hepatol. 2016 Dec;65(6):1232-1244. doi: 10.1016/j.jhep.2016.07.040. Epub 2016 Aug 8.

引用本文的文献

1
The Effect of Nutritional Education on Nutritional Status and Quality of Life in Patients with Liver Cirrhosis.
Healthcare (Basel). 2025 Aug 5;13(15):1905. doi: 10.3390/healthcare13151905.
3
Sarcopenia as a Risk Factor in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Implantation.
Diagnostics (Basel). 2025 Jun 5;15(11):1440. doi: 10.3390/diagnostics15111440.
4
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease.
Am J Gastroenterol. 2025 May 1;120(5):950-972. doi: 10.14309/ajg.0000000000003379. Epub 2025 May 2.
5
Current and emerging therapies for alcohol-associated hepatitis.
Liver Res. 2023 Mar 15;7(1):35-46. doi: 10.1016/j.livres.2023.03.002. eCollection 2023 Mar.
6
CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.
Acta Clin Croat. 2024 Apr;63(1):214-243. doi: 10.20471/acc.2024.63.01.26.
7
Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease.
Clin Liver Dis. 2024 Nov;28(4):731-745. doi: 10.1016/j.cld.2024.06.018. Epub 2024 Aug 13.
8
Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.
Front Pharmacol. 2024 Jul 16;15:1381476. doi: 10.3389/fphar.2024.1381476. eCollection 2024.
9
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations.
Bladder Cancer. 2021 Aug 31;7(3):261-278. doi: 10.3233/BLC-211536. eCollection 2021.
10
Association of Omega-3 Polyunsaturated Fatty Acids with Sarcopenia in Liver Cirrhosis Patients with Hepatocellular Carcinoma.
J Clin Transl Hepatol. 2024 Jul 28;12(7):613-624. doi: 10.14218/JCTH.2024.00036. Epub 2024 May 31.

本文引用的文献

1
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent.
Eur J Gastroenterol Hepatol. 2013 Jan;25(1):85-93. doi: 10.1097/MEG.0b013e328359a759.
3
Myostatin induces autophagy in skeletal muscle in vitro.
Biochem Biophys Res Commun. 2011 Dec 2;415(4):632-6. doi: 10.1016/j.bbrc.2011.10.124. Epub 2011 Nov 2.
4
Autophagy: renovation of cells and tissues.
Cell. 2011 Nov 11;147(4):728-41. doi: 10.1016/j.cell.2011.10.026.
5
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis.
J Gastroenterol Hepatol. 2012 Mar;27(3):430-41. doi: 10.1111/j.1440-1746.2011.06951.x.
6
Protein energy malnutrition predicts complications in liver cirrhosis.
Eur J Gastroenterol Hepatol. 2011 Nov;23(11):982-9. doi: 10.1097/MEG.0b013e32834aa4bb.
7
Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins.
Am J Physiol Cell Physiol. 2011 Dec;301(6):C1316-24. doi: 10.1152/ajpcell.00114.2011. Epub 2011 Sep 7.
8
Muscle wasting is associated with mortality in patients with cirrhosis.
Clin Gastroenterol Hepatol. 2012 Feb;10(2):166-73, 173.e1. doi: 10.1016/j.cgh.2011.08.028. Epub 2011 Sep 3.
9
Treating cancer cachexia to treat cancer.
Skelet Muscle. 2011 Jan 24;1(1):2. doi: 10.1186/2044-5040-1-2.
10
Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB.
Aging Cell. 2011 Dec;10(6):931-48. doi: 10.1111/j.1474-9726.2011.00734.x. Epub 2011 Aug 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验